GBG research at ESMO 2021


GBG research at ESMO 2021

We are happy to present our work at ESMO 2021, September 16-21th


Date: Sat, 18.09.2021, Lecture Time: 18:00 - 18:05,
Session: Mini oral session - Breast cancer, metastatic
Speakers: Sibylle Loibl (Neu-Isenburg, Germany)
Mini oral presentation #LBA19 A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (mBC) (DESIREE)
Loibl S, Schmidt M, Lübbe K, et al.


Date: Mon, 20.09.2021 Lecture Time: 18:08 - 18:13
Session: Mini oral session - Breast cancer, early stage
Speakers: José A. García-Saenz (Madrid, Spain)
Mini oral presentation #122MO Quality of life from the Penelope-B study on high-risk HR+/HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib
García-Sáenz JA, Marmé F, Rugo H, et al.

Session: ePosters
Speakers: Katya Galactionova (Basel, Switzerland)
ePoster#132P Health economic properties of Palbociclib in breast cancer patients with high risk of relapse following neoadjuvant therapy – results from the Penelope-B trial
Galactionova K, Loibl S, Salari P, et al.


Session: ePosters
Speakers: Frederik Marmé (Mannheim, Germany)
ePoster#199TiP Phase III postneoadjuvant study evaluating Sacituzumab Govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment – SASCIA
Marmé F, Hanusch C, Furlanetto J, et al.


Date: Fri, 17.09.2021
Session: Proffered Paper session - Breast cancer, early stage
Lecture Time: 14:20 - 14:30
Speakers: Sibylle Loibl (Neu-Isenburg, Germany)
Oral presentation #119O Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: BrighTNess, a randomized Phase 3 trial


Session: ePosters
Speakers: Sibylle Loibl (Neu-Isenburg, Germany)
ePoster#257P Health-related quality of life (HRQoL) in the ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)


GBG Forschungs GmbH
Dornhofstr. 10 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd